Cetraxate
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 34675-84-8 |
| PubChem (CID) | 2680 |
| ChemSpider | 2579 |
| UNII |
5VPA8CPF0N  |
| KEGG | D07663 |
| ChEMBL | CHEMBL502896 |
| Chemical and physical data | |
| Formula | C17H23NO4 |
| Molar mass | 305.36 g/mol |
| 3D model (Jmol) | Interactive image |
| |
Cetraxate (INN) is an oral gastrointestinal medication which has a cytoprotective effect.[1] Double-blind clinical trials in patients with gastric ulcer compared the effects of cetraxate with those of the drug gefarnate, a common standard drug treatment for gastric ulcer. Endoscopic examinations of patients treated with cetraxate showed cure rates of 28% after 4 weeks, 61% after 8 weeks, and 73% after 12 weeks of treatment, significantly higher than cure rates seen with gefarnate at both 8 and 12 weeks.[2]
References
- ↑ Kurebayashi Y, Ikeda T, Osada Y (January 1988). "Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats". Jpn. J. Pharmacol. 46 (1): 17–25. doi:10.1254/jjp.46.17. PMID 3367546.
- ↑ Ishimori A, Yamagata S, Taima T (1979). "Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (Cetraxate) on peptic ulcer. Multi-center clinical study". Arzneimittelforschung. 29 (10): 1625–32. PMID 391240.
This article is issued from Wikipedia - version of the 7/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.